Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Foxwoods Man, drkazmd65
Search This Board:
Last Post: 7/17/2014 11:10:19 PM - Followers: 157 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/



Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
  2. The scientific, clinical, and commercial development of the medicine and
  3. CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  
  2. Teva Pharmaceuticals Industries Ltd.
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  
  3.  
  4. Orient Europharma Co. Ltd.
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  
  5.  
  6. IDC-GP Pharm LLC 
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  
  7.  

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

News News Alert: CEL-SCI Receives Regulatory Clearance to Expand Phase III Head and Neck Cancer Trial into Turkey 07/22/2014 08:30:00 AM
PostSubject
#6080  Sticky Note University of Cincinnati Cancer Institute’s Comprehensive Head and Foxwoods Man 05/27/14 08:26:00 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#6178   I personally am not attending. learning curve 07/17/14 11:10:19 PM
#6177   Does anyone plan to attend the annual meeting Paleman 07/17/14 10:59:11 AM
#6176   More step-wise good news - another country has drkazmd65 07/17/14 09:07:56 AM
#6175   It would be nice if something would get tprosuper 07/15/14 10:49:02 AM
#6174   Guess the back burner has moved forward a Foxwoods Man 07/15/14 10:12:10 AM
#6173   LEAPS is on the back burner while CVM drkazmd65 07/11/14 11:04:43 AM
#6172   Good news? tprosuper 07/11/14 09:15:41 AM
#6171   Yet another slow step forward: drkazmd65 07/08/14 10:09:11 AM
#6170   From a logic perspective I would assume when learning curve 07/06/14 09:55:07 PM
#6169   I thought by sure the decision would be Foxwoods Man 07/01/14 04:38:23 PM
#6168   That's a very good question FM. That decision(should tprosuper 07/01/14 03:23:12 PM
#6167   Haven't heard a thing FM. drkazmd65 07/01/14 03:15:14 PM
#6166   I wonder what ever happened to that arbitrator? Foxwoods Man 07/01/14 10:21:08 AM
#6165   Agreed - slow progress is far better than drkazmd65 07/01/14 10:18:40 AM
#6164   nice premarket lift on the Multikine trial news puravida 07/01/14 08:59:14 AM
#6163   Speculation? Arrangement? Timing appears a bit away....not enough (small) re learning curve 06/29/14 10:57:09 AM
#6162   Very interesting and welcome "spike". Wish I knew tprosuper 06/28/14 01:23:29 PM
#6161   he make more than anyone their Foxwoods Man 06/28/14 07:04:19 AM
#6160   According to salary.com he make more than anyone their. eddie51 06/27/14 07:00:37 PM
#6159   Interesting spike up at the close,..... haven't seen drkazmd65 06/27/14 04:36:12 PM
#6158   Did he really? $2M? Wasn't last year a PlanTrader 06/25/14 04:00:56 PM
#6157   Maybe because he's Max De Clara's stepson? Astavakra 06/24/14 09:12:14 PM
#6156   I want to know why Geert rec'd 2 eddie51 06/24/14 07:21:19 PM
#6155   Did Geert say something? We're down a dime. Astavakra 06/24/14 04:09:55 PM
#6154   Awesome! Glad to hear that. Kami_ss 06/23/14 03:04:31 PM
#6153   Great news...... Foxwoods Man 06/23/14 01:41:36 PM
#6152   Excellent result Turney! Congratulations out your relative drkazmd65 06/23/14 01:41:07 PM
#6151   I guess I should have surgery more often. Turney 06/23/14 12:25:54 PM
#6150   I would have to generally agree with your drkazmd65 06/19/14 09:27:57 AM
#6149   This equity will move on news and not Foxwoods Man 06/18/14 05:31:57 PM
#6148   Because the 50 and 200 day moving average stockweiser 06/18/14 05:27:54 PM
#6147   I'll bite....Why? Foxwoods Man 06/18/14 05:07:26 PM
#6146   Need to close above 1.18 stockweiser 06/18/14 11:43:20 AM
#6145   Good luck on all fronts Turney. drkazmd65 06/17/14 10:25:51 PM
#6144   THANKS everyone for your concern I feel as Turney 06/17/14 06:45:08 PM
#6143   I will go under the knife Wednesday. Doc Turney 06/17/14 06:41:18 PM
#6142   I wish you the best Turney - may drkazmd65 06/17/14 12:58:35 PM
#6141   Sorry to hear. May I ask how you pijoe 06/17/14 11:50:09 AM
#6140   I hope everything turns out Ok for you.... Foxwoods Man 06/17/14 06:46:58 AM
#6139   Good luck. Hope it is not serious. Let Kami_ss 06/16/14 11:38:10 PM
#6138   Good luck learning curve 06/16/14 09:52:33 PM
#6137   I have a tumor on my salivary gland Turney 06/16/14 09:38:17 PM
#6136   It's not authored either. eddie51 06/13/14 09:34:14 PM
#6135   It might have been part of a packet Foxwoods Man 06/12/14 11:12:38 AM
#6134   I am somewhat skeptical as well FM - drkazmd65 06/12/14 11:08:18 AM
#6133   I thought so too learning curve 06/12/14 10:34:55 AM
#6132   Strange that a "letter to shareholders" was not Foxwoods Man 06/11/14 05:44:33 PM
#6131   Recently posted letter to shareholders - dated June, drkazmd65 06/11/14 10:03:30 AM
#6130   N warrants always keep talking to me... learning curve 06/06/14 03:28:12 AM
#6128   The only thing I can come up with learning curve 06/06/14 02:58:57 AM
PostSubject